Core Viewpoint - Picard Medical, Inc. has transitioned to public markets and is committed to advancing its Total Artificial Heart technology for patients with end-stage heart failure [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona and is the leader in total artificial heart technology for end-stage heart failure patients [3]. - SynCardia has developed the SynCardia Total Artificial Heart (STAH), the first artificial heart approved by both the FDA and Health Canada, and remains the only commercially available artificial heart in the U.S. and Canada [3]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and studied artificial heart globally [3]. Transition to Public Markets - The company will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking its transition to being a publicly traded entity [1]. - The CEO of Picard Medical expressed pride in this transition, emphasizing that it strengthens the company's ability to advance its artificial heart platform, including the fully implantable Emperor system [2]. Future Outlook - The transition to a public company is seen as an important phase for Picard Medical, as it aims to build on decades of clinical leadership and create long-term value through the advancement of next-generation technology [2].

Core Insights - Treace Medical Concepts has secured a new five-year $175 million senior secured loan arrangement to enhance its financial strength and flexibility [1][2] - The financing includes $60 million in term loans, $65 million in additional term loan availability, and a $50 million revolving credit facility [1][2] - The company aims to use the proceeds to prepay existing loans and strengthen its balance sheet while expanding its market presence [2][3] Financial Details - The new loan arrangement has a maturity date of five years, with an annual interest rate tied to the SOFR, subject to a minimum of 3% [2][4] - The term loan allows for 48 months of interest-only payments, extendable by an additional 12 months [2] - Following the refinancing, the company has approximately $165 million in total liquidity, including cash and unused credit facility availability [3] Company Overview - Treace Medical Concepts focuses on advancing surgical treatments for bunions and related midfoot deformities, addressing a significant market need with an estimated 67 million affected Americans [8] - The company has developed the patented Lapiplasty3D Bunion Correction System, which aims to correct bunion deformities in three dimensions [8] - Treace also offers various surgical systems and digital solutions to support surgeons and patients, enhancing its competitive position in the market [8]

Patrick (NASDAQ: PATK) is a leading component solutions provider serving the RV, Marine, Powersports and Housing markets. Since 1959, Patrick has empowered manufacturers and outdoor enthusiasts to achieve next- level recreation experiences. Our customer-focused approach brings together design, manufacturing, distribution, and transportation in a full solutions model that defines us as a trusted partner. Patrick is home to more than 85 leading brands, all united by a commitment to quality, customer service, ...

BEIJING, Dec. 18, 2025 /PRNewswire/ -- Scienjoy Holding Corporation ("Scienjoy", the "Company", or "we") (NASDAQ: SJ), a leading interactive entertainment company in the Chinese market, today announces its engagement of ICON Capital Group, LLC ("ICG") to evaluate strategic alternatives to optimize its substantial cash position and enhance long-term shareholder value. The engagement positions Scienjoy to explore multiple value-creation opportunities following several years of robust cash generation and sign ...

Atlanta, GA and Reno, NV, Dec. 18, 2025 (GLOBE NEWSWIRE) -- M2i Global, Inc. (“M2i,” the “Company,” “we,” “our” or “us”) (OTCQB: MTWO), a company specializing in the development and execution of a complete global value supply chain for critical minerals, along with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, applauds the recent December 11, 2025 announcement from the U.S. Department of State whereby Pax Silica, a U.S.-led strategic initiative to build a secure, prospero ...

Core Insights - Xcelerate, Inc. has made significant strategic adjustments in 2025 to align resources with long-term objectives, including the sale of its interest in ESN Group to strengthen its financial position and refocus on core missions [2][3] Financial Developments - The sale of ESN Group was an all-cash transaction that allowed Xcelerate to eliminate merchant finance debt associated with ESN, thereby improving its balance sheet [2] - The proceeds from the ESN sale, along with funds raised in a private placement, position the company to implement its AI-assisted patient portal program in early 2026 [3] Strategic Initiatives - Xcelerate is renewing its focus on AfiyaSasa Africa, LLC, aiming to launch an AI-assisted patient portal in Tanzania, which will connect patients in remote areas to clinicians [3][4] - The company is advancing its medical device patents, including a Surgical Tool with Targeting Guidance, and has filed additional applications in the EU and China [4] Communication and Engagement - To enhance transparency and shareholder engagement, Xcelerate is updating its corporate website and increasing its social media presence to share insights and progress updates [5] - A dedicated Investor Relations email will be established to streamline communication with shareholders [5] Future Outlook - In 2026, Xcelerate plans to carefully advance its key initiatives, particularly the AfiyaSasa platform, with a focus on testing technology in clinical settings and refining operations [6] - The company aims to maintain regular updates and transparent communication with shareholders as it progresses with AI-driven healthcare solutions [6]

Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award SecuredTORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting significant progre ...

DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the ...

ANDOVER, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced that it will ring the Nasdaq Stock Market Opening Bell on December 22, 2025. The event will take place at the Nasdaq MarketSite in New York’s Times Square and will feature CEO Byrna Ganz and members of the Company’s leadership team ...

Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Palamina Corp. (TSXV: PA) (OTCQB: PLMNF) has acquired 100% of the mineral rights to the Esperanza concession covering a 60.75 hectare area located in the Santa Lucia district in southeastern Peru. Esperanza lies adjacent to Aftermath Silver Ltd.'s (TSXV: AMM) Berenguela silver copper manganese project which is hosted within a surface area of approximately 50 hectares. Berenguela hosts a current mineral resource estimate of 122.5 million ounces of sil ...